Ashley Brown, Ph.D.

Ashley BrownAshley Brown, Ph.D.
Associate Professor
Institute for Therapeutic Innovation
Department of Medicine

Institute for Therapeutic Innovation
6550 Sanger Road
Orlando, FL 32827
ashley.brown@medicine.ufl.edu

 

Antiviral Pharmacodynamics Laboratory 

 

 

Degree/Program

Institution

Field/Specialty

PhD University at Albany, State University of New York Infectious Disease and Immunology
BA Miami University Microbiology; Minor: Molecular Biology

Professional Societies/Memberships

2002- Present American Society for Microbiology

2014- Present Infectious Diseases Society of America

2008- 2010 International Society for Antiviral Research

2005- 2009 American Society for Virology

 

Awards/Recognition

2017 University of Florida Term Professorship Award for outstanding academic and research achievements (3 year award)

2015 University of Florida Excellence Award for Assistant Professors

 

Publications

  • Book Chapters:

Drusano, G.L. and A.N. Brown (2014). Pharmacometrics in Viral Infections. In Schmidt, S. and Derendorf, H. (ed), Applied Pharmacometrics, AAPS Advances in the Pharmaceutical Sciences Series, Vol. 14. Springer, New York, New York.

  • Peer-Reviewed Research articles:

Franco, E.J., J.L. Rodriquez, J.J. Pomeroy, K.C. Hanrahan, and A.N. Brown (2018). The Effectiveness of Antiviral Agents with Broad-Spectrum Activity against Chikungunya Virus Varies Between Host Cell Lines. Antivir. Chem. Chemother. 26: 1-7.

Pires de Mello, C.P., X. Tao, M. Vicchiarelli, J.B. Bulitta, A. Kaushik, and A.N. Brown (2018). Clinical Regimens of Favipiravir Inhibit Zika Virus (ZIKV) Replication in the Hollow Fiber Infection Model (HFIM) System. Antimicrob. Agents Chemother. 62:e00967-18.

Pires de Mello, C.P., G.L. Drusano, J.L. Rodriquez, and A.N. Brown (2018). Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus (DENV) in the Hollow Fiber Infection Model (HFIM) System. Viruses. 10:317.

Kaushik, A., A. Yndart, S. Kumar, R.D. Jayant, A. Vashist, A.N. Brown, C-Z. Li, and M. Nair (2018). A Sensitive Electrochemical Immunosensor for Label-Free Detection of Zika-virus Protein. Sci Reports. 8:9700.

Ande, A., T. Vaidya, B.N. Tran, M. Vicchiarelli, A.N. Brown, and S. Ait-Oudhia (2018). Utility of a Novel Three Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer. Front. Pharmacol. 9:403.

Pires de Mello, C.P., X. Tao, T-H. Kim, J.B. Bulitta, J.L. Rodriquez, J.J. Pomeroy, and A.N. Brown (2018). Zika virus (ZIKV) Replication is Substantially Inhibited by Novel Favipiravir and Interferon-alpha Combination Regimens. Antimicrob. Agents Chemother. 62:e01983-17.

Pires de Mello, C.P., G.L. Drusano, J.R. Adams, M. Shudt, R. Kulawy, and A.N. Brown (2018). Oseltamivir-Zanamivir Combination Therapy Suppresses the Amplification of Drug-Resistant H1N1 Influenza A viruses in the Hollow Fiber Infection Model (HFIM) System. Eur J Pharm Sci. 111: 443-449.

Brown, A.N., L. Liu, J.L. Rodriquez, L. Zhao, L. Schuster, E. Li, G.P. Wang, M.N. Neely, W. Yamada, and G.L. Drusano (2017). Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Sci Reports. 7:14421.

Pomeroy, J.J., G.L. Drusano, J.L. Rodriquez, and A.N. Brown (2017). Searching for Synergy: Identifying Optimal Antiviral Combination Therapy Using Hepatitis C Virus (HCV) Agents in a Replicon System. Antiviral Res. 146, 149-152.

Fleisher, B., A.N. Brown, and S. Ait-Oudhia (2017). Application of Translational Pharmacometrics and Quantitative Systems Pharmacology to Cancer Therapy: The Example of Luminal A Breast Cancer. Pharmacol Res. 124, 20-33.

Brown, A.N., K.M. Gallegos, D.Z. D’Argenio, and G.L. Drusano (2017). Reply to Scagnolari et al. J. Infect. Dis. 215, 493-494.

Gallegos, K.M., G.L. Druasno, D.Z. D’Argenio, and A.N. Brown (2016). Chikungunya Virus: In Vitro Response to Combination Therapy with Ribavirin and Interferon Alfa 2a. J. Infect. Dis. 214, 1192-1197.

Brown, A.N., G.L. Drusano, J.R. Adams, J.L. Rodriquez, K. Jambunathan, D.L. Baluya, D.L. Brown, A. Kwara, J.C. Mirsalis, R. Hafner, and A. Louie (2015). Preclinical Evaluations to Identify Optimal Linezolid Regimens for Tuberculosis Therapy. mBio 6(6):e01741-15.

Brown, A.N., J.R. Adams, D.L. Baluya, and G.L. Drusano (2015). Pharmacokinetic Determinants of Virological Response to Raltegravir in the In Vitro Pharmacodynamic Hollow Fiber Infection Model (HFIM) System. Antimicrob. Agents Chemother. 59, 3771-3777.

Brown, A.N., J.J. McSharry, J.R. Adams, R. Kulawy, R.J.O. Barnard, W. Newhard, A. Corbin, D.J. Hazuda, A. Louie, and G.L. Drusano (2012). Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a Novel In Vitro Pharmacodynamic System. Antimicrob. Agents Chemother. 56, 1170-1181.

Brown, A.N., J.J. McSharry, Q. Weng, J.R. Adams, R. Kulawy, and G.L. Drusano (2011). Zanamivir, at 600 mg Twice Daily, Inhibits Oseltamivir-Resistant 2009 pandemic H1N1 Influenza Virus in an in vitro Hollow Fiber Infection Model System. Antimicrob. Agents Chemother. 55, 1740-1746.

Brown, A.N., J.B. Bulitta, J.J. McSharry, Q. Weng, J.R. Adams, R. Kulawy, and G.L. Drusano (2011). The Effect of Half-Life on the Pharmacodynamic Index of Zanamivir as Delineated by a Mathematical Model. Antimicrob. Agents Chemother. 55, 1747-1753.

Appler, K.K., A.N. Brown, B.S. Stewart, M.J. Behr, V.L. Demarest, S.J. Wong, and K.A. Bernard (2010). Persistence of West Nile virus in the Central Nervous System and Periphery of Mice. PLoS ONE 5(5): e10649. doi:10.1371/journal.pone.0010649.

Brown, A.N., J.J. McSharry, Q. Weng, E.M. Driebe, D.M. Engelthaler, K. Sheff, P.S. Keim, J. Nguyen, and G.L. Drusano (2010). An in vitro system for modeling Influenza A virus Resistance under drug pressure. Antimicrob. Agents Chemother. 54, 3442 – 3450.

McSharry, J.J, Q. Weng, A.N. Brown, R. Kulawy, and G.L. Drusano (2009). Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for Influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 53, 2375-2381.

Brown, A.N., K.A. Kent, C.J. Bennett, and K.A. Bernard (2007). West Nile virus tropism, burden, and kinetics of spread are similar between two mouse strains with different survival rates during acute infection. Virology 368, 422-430.

  • Peer-Reviewed Presented Abstracts:

Jambunathan, K., K.M. Gallegos, J.C. Mirsalis, and A.N. Brown (2018). An in vitro Evaluation of Linezolid-Associated Mitochondrial Toxicity in K562 cells, in Abstracts presented at the 57th Meeting of the Society of Toxicology.

Vaidya, T., A. Ande, B.N. Tran, A.N. Brown, and S. Ait-Oudhia (2018). Systems Pharmacological Analysis of a Tumor Priming Combination Therapy to Overcome HER2 and mTOR Therapies Resistance in Breast Cancer, in Abstracts presented at the 2018 American Society for Clinical Pharmacology and Therapeutics Annual Meeting.

Tao, X., C.P. Pires de Mello, T-H. Kim, J.B. Bulitta, J.L. Rodriquez, J.J. Pomeroy, and A.N. Brown (2017). Establishing A Novel Combination Therapy Against Zika Virus (ZIKV) by a Translational, Mechanism-Based Model, in Abstracts presented at the 2017 American Association of Pharmaceutical Sciences Annual Meeting and Exposition.

Pires de Mello, C.P., G.L. Drusano, J. Pomeroy, E.J. Franco, J.L. Rodriquez, and A.N. Brown (2017). Therapeutic Potential of Interferon-alpha and Ribavirin as Combination Therapy against Dengue Virus in different Cell Lines, in Abstracts presented at the 66th Meeting of the American Society of Tropical Medicine & Hygiene.

Pires de Mello, C.P., X. Tao, T.H. Kim, J.B. Bulitta, J.L. Rodriquez, J.J. Pomeroy, and A.N. Brown (2017). Zika virus (ZIKV) Replication is Substantially Inhibited by Novel Favipiravir and Interferon-alpha Combination Regimens, presented at the Cell Symposia:Emerging and Re-emerging viruses.

Pires de Mello, C.P., G.L. Drusano, J. Pomeroy, E.J. Franco, J.L. Rodriquez, and A.N. Brown (2017). Combination Therapy with Interferon-alpha and Ribavirin: An Effective Antiviral Strategy Against Dengue Virus?, in Abstracts presented at the 2nd American Society for Microbiology Microbe.

Ande, A., B.N. Tran, A.N. Brown, and S. Ait-Oudhia (2017). Novel Three Dimensional and Dynamic (3DD) Cell Culture System for Optimization of Molecularly Targeted Combination Therapy in Dual HER2 and mTOR Refractory Breast Cancer, in Abstracts presented at the 2017 Experimental Biology meeting.

Brown, A.N., A. Louie, J. Adams, K. Jambunathan, D. Baluya, R. Hafner, and G.L. Drusano (2014). Relationship between Linezolid (LZD) Exposure Profiles and Toxicity in the Hollow Fiber Infection Model (HFIM) System, in Late Breaker Abstracts presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Brown, A.N., J.J. McSharry, R. Kulawy, C. Fenwick, R. Bethell, J. Duan, J. Kort, P. Robinson, B. Simoneau, C. Yoakim, and G.L. Drusano (2011). Pharmacodynamics of BI 224436 for HIV in an In Vitro Hollow Fiber Infection Model System, in Abstracts presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.

Brown, A.N., J.B. Bulitta, J.J. McSharry, J.R. Adams, R. Kulawy, and G.L. Drusano (2011). Efficacy of Oseltamivir (OS) / Zanamivir (ZA) Combination Chemotherapy for Two Drug-Resistant H1N1 Influenza A Viruses in the Hollow Fiber Infection Model (HFIM), in Abstracts presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.

Brown, A.N., J.J. McSharry, Q. Weng, R. Kulawy, J.B. Bulitta, and G.L. Drusano (2010). Explaining the dynamically linked PK/PD index for zanamivir against oseltamivir resistant H1N1 influenza virus via mechanism-based mathematical modeling, in Abstracts presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Brown, A.N., J.J. McSharry, R.J.O. Barnard, W. Newhard, A. Corbin, D.J. Hazuda, and G.L. Drusano (2010). The effect of a serine protease inhibitor (MK-4519) on Hepatitis C virus replicons using an in vitro pharmacodynamic system, in Abstracts presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Brown, A.N., D. Singer, J.J. McSharry, R.J.O Barnard, D.J. Hazuda, and G.L. Drusano (2010). In vitro dose ranging studies for serine protease inhibitor, MK-4519, against a Hepatitis C virus (HCV) replicon using the BelloCell system, in Abstracts presented at the 23rd International Conference on Antiviral Research.

Brown, A.N., D.V. Singer, J.J. McSharry, and G.L. Drusano (2009). Determination of optimal dosing strategies of anti-Hepatitis C virus compounds using the BelloCell system, in Abstracts presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Brown, A.N., G.L. Drusano, D.V. Singer, and J.J. McSharry (2009). Use of the BelloCell system to determine the effect of Ribavirin on the expression of an hepatitis C virus replicon in 2209-23 cells, in Abstracts presented at the 22nd International Conference on Antiviral Research.

Brown, A.N. And K.A. Bernard (2008). West Nile virus alters lymphocyte populations in two mouse strains with different survival rates, in Abstracts presented at the 27th Annual Meeting of the American Society for Virology.

Brown, A.N. and K.A. Bernard (2008). West Nile virus infects B lymphocytes, in Abstracts presented at the Keystone Symposia Viral Immunity Conference.

Brown, A.N., M.J. Behr and K.A. Bernard (2007). West Nile infection in mice results in a lymphopenia, in Abstracts presented at the 10th Annual Meeting of the Upstate New York Immunology Conference.

Brown, A.N., M.J. Behr, V.L. Demarest, S.J. Wong, and K.A. Bernard (2007). West Nile virus alters lymphocyte cell populations and results in lymphopenia in infected mice, in Program and abstracts presented at the 26th Annual Meeting of the American Society for Virology.

Brown, A.N., K.A. Kent, M.J. Behr and K.A. Bernard (2006). A quantitative and histopathological analysis of West Nile virus infection in the central nervous system of mice with and without disease, in Abstracts presented at the 41st Annual Regional Meeting of the American Society for Microbiology.

K.A. Kent, A.N. Brown, C.J. Bennett, A.P. Dupuis, II, L.D. Kramer and K.A. Bernard (2006). In vivo persistence of West Nile virus, in Program and abstracts presented at the 25th Annual Meeting of the American Society for Virology.

Brown, A.N., K.A. Kent, M.J. Behr and K.A. Bernard (2006). Histopathology of West Nile virus infection in mice with and without disease, in Program and abstracts presented at the 25th Annual Meeting of the American Society for Virology.

Brown, A.N., K.A. Kent, M.J. Behr and K.A. Bernard (2005). Comparison of West Nile virus infection in mice with and without disease, in Program and abstracts of the 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene.

Kent, K.A., A.N. Brown and K.A. Bernard (2005). West Nile Persistence in mice, in Abstracts presented at the 2005 Annual Biomedical Sciences Research Conference.

Brown, A.N., K.A. Kent and K.A. Bernard (2005). The correlation between West Nile virus load and disease in mice, in Abstracts presented at 2005 Annual Biomedical Sciences Research Conference.

Brown, A.N., K.A. Kent and K.A. Bernard (2005). Comparison of West Nile virus replication in resistant and susceptible mouse strains, in Program and abstracts of the 24th Annual Meeting of the American Society of Virology.

Brown, A.N., K.A. Kent and K.A. Bernard (2004). The evaluation of host IgM production and the onset of West Nile disease in a mouse model, in Abstracts presented at 2004 Annual Biomedical Sciences Research Conference.